At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 135 enrolled
Drug / intervention
placebo +3 moredrug
Likely dose
PF-00489791 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF PF-00489791 IN SUBJECTS WITH STAGE 1 AND 2 ESSENTIAL HYPERTENSION USING AMBULATORY BLOOD PRESSURE MONITORING (ABPM)
In Brief
A Phase 2 clinical trial evaluating placebo and PF-00489791 for Hypertension. Completed, enrolled 135 participants across 20 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartFeb 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedJan 17, 2007
Enrollment StartFeb 27, 2007
Primary CompletionJan 28, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.5 years ago
Interventions
placebodrug
placebo, oral, tablets, once daily, for 28 days
PF-00489791drug
PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
PF-00489791drug
PF-00489791 4 mg, oral, tablets, once daily, for 28 days
PF-00489791drug
PF-00489791 10 mg, oral, tablets, once daily, for 28 days